Adagio Says New Data Highlight Potential Of ADG20 For Treatment And Prevention Of Covid-19

Adagio Therapeutics Inc. (ADGI) announced new data highlighting the potential of ADG20 for the treatment and prevention of covid-19.

ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2.

According to the company, ADG20 continues to be well tolerated in healthy volunteers with prolonged half-life and serum virus neutralization activity observed out to six months in ongoing phase 1 study.

The company noted that data from quantitative systems pharmacology/whole-body physiologically based pharmacokinetic modeling support evaluation of 300 mg intramuscular dose of ADG20 given as a single intramuscular injection in ongoing phase 2/3 studies.

"The continued strength of the safety and pharmacokinetic data from our Phase 1 study is encouraging and further underscores the potential impact an antibody like ADG20 - which was designed to be potent, broadly neutralizing and delivered as a single IM injection - could have on people with or at risk of COVID-19," said Lynn Connolly, chief medical officer of Adagio.

The company stated that the phase 1 data combined with its dose selection strategy have allowed the company to initiate and advance its pivotal trials of ADG20 in the treatment and prevention of COVID-19.

The company anticipates the data will support an Emergency Use Authorization application in the first quarter of 2022, which could enable the company to bring an important treatment option to patients.

The company said data will be presented during IDWeek 2021 and 19th annual discovery on target conference on September 30, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Delta Air Lines is set to resume flights on its routes between the U.S. and Japan from October 30, 2002 in anticipation of easing of COVID-19-related travel restrictions, which were put in place two years ago. The airline joins American Airlines and United Airlines, who have reportedly announced the resumption of flights to Japan. Tech major Apple Inc. has asked corporate employees to return to offices at least three days a week by September 5, Bloomberg reported. The latest deadline was issued following several delays to its previous deadlines amid a resurgence in COVID-19 cases. As per the report, the company will require employees to work from offices on Tuesdays, Thursdays and a regular third day to be determined by... Retail giant Walmart reported Tuesday a net profit for the second quarter that grew 20.4 percent from last year, reflecting lower operating expenses and partially inflation driven revenue growth. The results were also driven by the rebound in international markets. Quarterly revenues topped analysts' expectations. The retailer also raised its adjusted earnings guidance for the full-year 2023.
Follow RTT